Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cellmid (CDY) has appointed Dr Dominic Burg as Chief Operating Officer (COO) effective from July 1
  • Dr Burg joined the company in March 2016 and was previously Vice President and then Director of Operations
  • Dr Burg is an experienced scientist, undertaking his PhD studies at the University of NSW School of Biotechnology and Biomolecular sciences
  • In this role, he will continue to use his strong scientific and strategic thinking to help the company
  • Cellmid is steady on the market today and shares have been trading for 18.5 cents each since May 5

Cellmid (CDY) has appointed Dr Dominic Burg as Chief Operating Officer (COO) effective from July 1.

Dr Burg joined Cellmid in March 2016 and was previously Vice President and then Director of Operations.

He has played a pivotal role in the company’s growth, being a key driver of the Evolis consumer brand. He has also helped improve operational efficiencies across Cellmid’s consumer and biotechnology businesses.

Dr Burg is an experienced scientist, undertaking his PhD studies at the University of NSW School of Biotechnology and Biomolecular sciences.

Once he completed these studies, he underwent post-doctoral training at the University of Sydney, studying the systems biology of complex inflammatory processes.

During his academic career, Dr Burg worked in partnership with the pharmaceutical industry and ran complex projects using his analytical and strategic capabilities.

“I am grateful for the opportunity and excited to continue to work with our team to deliver Cellmid’s strategic objectives,” Dr Burg commented. 

“I am particularly looking forward to driving operational profitability for our consumer business and growing our diagnostic assets,” he said.

In this role, Dr Burg will continue to use his strong scientific and strategic thinking to help the company.

“Dominic is an exceptional professional with whom I had the pleasure of working for the past four years,” CEO Maria Halasz said. 

“He is highly respected by all of us at Cellmid, our employees, directors, and partners. I am very much looking forward to working with Dominic in a more strategic role,” she added.

Cellmid is steady on the market today and shares have been trading for 18.5 cents each since May 5.

CDY by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.